Long-term follow-up phase I/II trial of NX 1207 in patients with benign prostatic hyperplasia.
Phase of Trial: Phase I/II
Latest Information Update: 25 Mar 2011
At a glance
- Drugs Fexapotide (Primary)
- Indications Benign prostatic hyperplasia
- Focus Adverse reactions; Therapeutic Use
- 25 Mar 2011 Results from a 7.5-year follow up have been reported in a Nymox media release.
- 16 Mar 2011 Status changed from active, no longer recruiting to completed.
- 06 May 2010 Positive 6-year follow-up results reported in a media release from Nymox.